从“一苗难求”到随时可打,这几年来,HPV疫苗在国内的供需情况发生了显著变化。近日,默沙东在公布2024年业绩情况时宣布,将暂停向中国市场供应HPV疫苗(Gardasil/Gardasil 9)。2月6日,默沙东方面向北京商报记者回应称,这一举措是根据消费者需求的动态变化,阶段性调整中国市场的发货节奏,预计将于年中逐步恢复常态。在业内人士看来,默沙东作出这一决定并不意外。截至2024年三季度末,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.